News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Seeks To Outbid Rival Endo Health Solutions Inc. (ENDP) With $114 Million NuPathe Inc. (PATH) Offer


1/8/2014 7:19:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries Ltd. (TEVA) offered at least $114 million to acquire U.S. migraine treatment maker NuPathe Inc. (PATH:US), seeking to outbid a previous offer from Endo Health Solutions Inc. (ENDP:US) Teva offered to pay $3.65 a share, plus as much as $3.15 a share if sales goals are achieved related to the migraine drug Zecuity, NuPathe said today in a corporate filing (PATH:US). Endo’s offer, announced Dec. 16, was for $105 million in cash plus as much as $3.15 per share in milestone payments.

Help employers find you! Check out all the jobs and post your resume.

Read at BusinessWeek
Read at Reuters
Read at Globes Online
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES